In the last few days there were many news stories about the upcoming Phase I Ebola vaccine trials in the national and international press, e.g.:
The trial including 60 heatlhy volunteers is led by Prof Adrian Hill from the Jenner Institute, and the CBF will play an important role in helping the trial to commence asap after ethics and regulatory approvals are received. The adenovirus vaccine was developed by Glaxo Smith Kline (GSK) and the US National Institute of Health (NIH) and will be imported, labelled and QP certified at the CBF for use in clinical trial. If no adverse reactions are found in the initial study, the trial
will be extended to include volunteers in The Gambia and Mali.